Home » Newsletters » BioWorld Science

BioWorld Science

April 10, 2000

View Archived Issues

Hybridon presents preclinical results with MDM2 antisense compound at AACR

ImClone Systems reports positive preclinical data from gp75 melanoma vaccine study

Celtrix receives U.S. patent for use of SomatoKine as diabetes therapy

Intranasal morphine pilot clinical trial results reported

Obesity drug slated to enter phase I trials next month

Alizyme's phase IIa trial of renzapride is fully enrolled

Hepatitis B vaccine incorporating new adjuvant requires fewer doses, has enhanced efficacy

NeoTherapeutics completes enrollment in phase IIb Neotrofin trial and initiates open-label extension

Progenics reports HIV therapy progress at Keystone symposium

Gilead licenses NX-1838, a new AMD treatment, to EyeTech

Janssen to discontinue development of R-121919 and substitute with a backup compound

Formamide compounds from Glaxo Wellcome inhibit TNF-alpha release and MMP activity

Scotia and Techniclone sign letter of intent related to licensing of VTA

New class of matrix metalloproteinase inhibitors in development by AstraZeneca

Abbott designs macrolide LHRH antagonists

Dendreon describes preparation and use of apoptosis-inducing HLA-DR-specific MAbs

Immune Network Research and Bridge Pharma expand joint venture

Novel serotonergic compounds from Cerebrus particularly useful for obesity Rx

BMS synthesizes new potassium channel blockers for cardiac arrhythmias

SkyePharma and Amgen sign development contract

Small-molecule chemokine receptor antagonists jointly developed by LeukoSite and Kyowa Hakko

Psoriatic arthritis patients sought for clinical trial

Sultams prove to be potent NNRTIs in biological screens; work presented at ACS meeting

Cogent Neuroscience secures funds to accelerate neuroprotective gene discovery program

TBC-3342: a potent urea VLA-4 antagonist designed at Texas Biotechnology

Wyeth Lederle Vaccines gains expanded access to Corixa's MPL adjuvant

Cannabinoid receptor affinity probes designed by U. of Connecticut scientists

Highly potent, non-thiol-containing FTase inhibitor characterized by BMS at AACR meeting

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...